1 Title

2 Constructing personalized characterizations of structural brain aberrations in patients with

- 3 dementia and mild cognitive impairment using explainable artificial intelligence
- 4

5 Authors

- 6 Esten H. Leonardsen^{1,2,*}, Karin Persson^{3,4}, Edvard Grødem^{1,5}, Nicola Dinsdale⁶, Till
- 7 Schellhorn^{7,8}, James M. Roe¹, Didac Vidal-Piñeiro¹, Øystein Sørensen¹, Tobias Kaufmann^{2,9,10},
- 8 Eric Westman¹¹, Andre Marquand¹², Geir Selbæk^{3,4}, Ole A. Andreassen^{2,13}, Thomas
- 9 Wolfers^{1,2,9,10,†}, Lars T. Westlye^{1,2,13,†}, Yunpeng Wang^{1,†} for the Alzheimer's Disease
- 10 Neuroimaging Initiative[‡] and the Australian Imaging Biomarkers and Lifestyle flagship study of
- 11 ageing[§]
- 12

13 Affiliations

- 14 1. Department of Psychology, University of Oslo, Oslo, Norway
- 15 2. Norwegian Centre for Mental Disorders Research (NORMENT), Oslo University Hospital &
- 16 Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 17 3. The Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, Norway
- 18 4. Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway
- 19 5. Computational Radiology & Artificial Intelligence (CRAI) Unit, Division of Radiology
- 20 and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
- 21 6. Oxford Machine Learning in NeuroImaging (OMNI) Lab, University of Oxford, UK
- 22 7. Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 8. Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
- 24 9. Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health, University
- 25 of Tübingen, Germany
- 26 10. German Center for Mental Health (DZPG)
- 27 11. Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society,
- 28 Karolinska Institutet, Stockholm, Sweden
- 29 12. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre,
- 30 Nijmegen, Netherlands
- 31 13. KG Jebsen Center for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway

- 33 † These authors contributed equally
- ³⁴ ‡ Data used in preparation of this article were obtained from the Alzheimer's Disease
- 35 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within
- 36 the ADNI contributed to the design and implementation of ADNI and/or provided data but did
- 37 not participate in analysis or writing of this report. A complete listing of ADNI investigators can
- 38 be found at: <u>http://adni.loni.usc.edu/wp-</u>
- 39 <u>content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</u>
- 40 § Data used in the preparation of this article was obtained from the Australian Imaging
- 41 Biomarkers and Lifestyle flagship study of ageing (AIBL) funded by the Commonwealth
- 42 Scientific and Industrial Research Organisation (CSIRO) which was made available at the ADNI
- 43 database (<u>www.loni.usc.edu/ADNI</u>). The AIBL researchers contributed data but did not
- 44 participate in analysis or writing of this report. AIBL researchers are listed at www.aibl.csiro.au.
- 45
- 46 * Corresponding author:
- 47 Esten H. Leonardsen,
- 48 Forskningsveien 3A, Harald Schjelderups hus, 0373 Oslo, Norway,
- 49 <u>estenhl@uio.no</u>
- 50

51 Abstract

Deep learning approaches for clinical predictions based on magnetic resonance imaging data 52 have shown great promise as a translational technology for diagnosis and prognosis in 53 neurological disorders, but its clinical impact has been limited. This is partially attributed to the 54 opaqueness of deep learning models, causing insufficient understanding of what underlies their 55 decisions. To overcome this, we trained convolutional neural networks on structural brain scans 56 to differentiate dementia patients from healthy controls, and applied layerwise relevance 57 propagation to procure individual-level explanations of the model predictions. Through extensive 58 59 validations we demonstrate that deviations recognized by the model corroborate existing knowledge of structural brain aberrations in dementia. By employing the explainable dementia 60 classifier in a longitudinal dataset of patients with mild cognitive impairment, we show that the 61 spatially rich explanations complement the model prediction when forecasting transition to 62 dementia and help characterize the biological manifestation of disease in the individual brain. 63 Overall, our work exemplifies the clinical potential of explainable artificial intelligence in 64 precision medicine. 65

66 Introduction

Since its invention in the 1970s, magnetic resonance imaging (MRI) has provided an opportunity 67 to non-invasively examine the inside of the body. In neuroscience, images acquired with MRI 68 69 scanners have been used to identify how the brains of patients with various neurological disorders differ from their healthy counterparts. Stereotypically, this has been done by collecting 70 data from a group of patients with a given disorder and a comparable group of healthy controls, 71 on which traditional statistical inference is applied to identify spatial locations of the brain where 72 the groups differ ¹. Typically, these locations are not atomic locations identified by spatial 73 74 coordinates, but rather morphological regions defined by an atlas, derived from empirical or theoretical insights of how the brain is structured. Differences between groups are described 75 using morphometric properties like thickness or volume of these prespecified regions. A major 76 benefit of this approach is the innate interpretability of the results: on average, patients with a 77 78 given disorder deviate in a specific region of the brain in a comprehensible manner. Furthermore, the high degree of localization offered by modern brain scans allows for accurate 79 80 characterization of where and how the brain of an individual deviates from an expected, typically

healthy, norm². However, the effects which are found are typically small³ with limited 81 predictive power at the individual level ^{4,5}, which in turn has raised questions about whether 82 these analytical methods are expressive enough to model complex mental or clinical phenomena 83 ⁶. As an alternative, new conceptual approaches are proposed, advocating modelling frameworks 84 with increased expressive power that allow for group differences through complex, non-linear 85 interactions between multiple, potentially distant, parts of the brain⁷, with a focus on prediction 86 87 ⁸. Such modelling flexibility is naturally achieved with artificial neural networks (ANNs), a class of statistical learning methods that combines aspects of data at multiple levels of abstraction, to 88 accurately solve a predictive task ⁹. However, while this often yields high predictive 89 performance, e.g. by demonstrating clinically sufficient case-control classification accuracy for 90 certain conditions, it comes at the cost of interpretation, as the models employ decision rules not 91 trivially understandable by humans ¹⁰. When the goal of the analysis is clinical, supporting the 92 diagnosis and treatment of someone affected by a potential disorder, this opaqueness presents a 93 substantial limitation. Thus, development and empirical validation of new methods within 94 clinical neuroimaging that combine predictive efficacy with individual-level interpretability is 95 imperative, to facilitate trust in how the system is working, and to accurately describe inter-96 individual heterogeneity. 97

98

With more than 55 million individuals afflicted worldwide ¹¹, over 25 million disability-adjusted 99 life years lost ^{12,13} and a cost exceeding one trillion USD yearly ¹⁴, dementia is a prime example 100 of a neurological disorders that incur a monumental global burden. Due to the global aging 101 population the prevalence is expected to nearly triple by 2050¹⁵, inciting a demand for 102 technological solutions to facilitate handling the upcoming surge of patients. Dementia is a 103 complex and progressive clinical condition ¹⁶ with multiple causal determinants and moderators. 104 Alzheimer's disease (AD) is the most common form and accounts for 60%-80% of all cases ¹¹. 105 However, the brain pathologies underlying different subtypes of dementia are not disjoint, but 106 often co-occur^{17–19}, and have neuropathological commonalities²⁰. The most prominent is 107 108 neurodegeneration, occurring in both specific regions like the hippocampus, and globally across the brain ²¹, and inter-individual variations in the localization of atrophy has been associated with 109 impairments in specific cognitive domains^{22,23}. Thus, the biological manifestation of dementia in 110 the brain is heterogeneous 24 , resulting in distinctive cognitive and functional deficits 20 , 111

112 highlighting the need for precise and personalized approaches to diagnosis. For patients with

113 mild cognitive impairment (MCI), a potential clinical precursor to dementia, providing

114 individualized characterizations of the underlying etiological disease at an early stage could

115 widen the window for early interventions 25 , alleviate uncertainty about the condition, and help

116 with planning for the future 26 .

117

In dementia, ANNs, and particularly convolutional neural networks (CNNs), have been applied 118 to brain MRIs to differentiate patients from controls ^{27,28}, prognosticate outcomes ²⁹, and 119 differentially diagnose subtypes ³⁰. However, while research utilizing this technology has been 120 influential, clinical translations are scarce ³¹. Where techniques for segmenting brain tumours or 121 detecting lesions typically produce segmentation masks that are innately interpretable, predicting 122 a complex diagnosis would entail compressing all information contained in a high-dimensional 123 brain scan into a single number. Using deep learning, the decisions underlying this immense 124 reduction are obfuscated, both from the developer of the system, the clinical personnel using it, 125 and the patient ultimately impacted by the decision. This black box nature is broadly credited for 126 the low levels of adoption in safety-critical domains like medicine ³². Responding to this 127 limitation, explainable artificial intelligence (XAI) provides methodology to explain the 128 behaviour of ANNs³³. The nature of these explanations varies, e.g. by what type of model is to 129 be explained, what conceptual level the explanation is at, and who it is tailored for ^{34,35}. In 130 131 computer vision, XAI typically aims for post-hoc explanations of individual decisions, explaining why a model arrived at a given prediction for a given image. Explanations are often 132 provided in a visual format, as a heatmap indicating how different regions of the image 133 contribute to the prediction ³⁶. Layerwise Relevance Propagation (LRP) is a variant of such a 134 135 method, based on propagating relevance from the prediction-space, backwards through all layers of the model to the image-space, to form a relevance map ³⁷. A major advantage of LRP is its 136 intuitive interpretation: by construction, the total amount of relevance which denotes contribution 137 to the prediction is kept fixed between layers. Thus, the relevance propagated back to an input 138 139 voxel is directly indicative of the influence of that exact voxel to the prediction. Recently, several studies have applied both LRP and other explainable AI methods to dementia³⁸, finding 140 that the heatmaps generally highlight regions known to change in dementia $^{39-42}$. However, the 141 possibility of utilizing the fine-grained, individual, heatmaps produced by LRP to accurately 142

characterize individualized disease manifestations has not been explored, despite its potential for
 supporting clinical decisions towards precision medicine ^{41,43}.

In the present study, we applied techniques from deep learning and XAI on MRI scans of the 145 brain to make explainable and clinically relevant predictions for dementia at the individual level 146 (Figure 1). Using a state-of-the-art architecture for neuroimaging data, we trained CNNs to 147 differentiate patients diagnosed with dementia from healthy controls based on T1-weighted 148 149 structural MRIs. We implemented LRP on top of the trained models to form a computational pipeline producing individual-level explanations in the form of relevance maps alongside the 150 151 model predictions. The relevance maps were validated in a subset of dementia patients, both in a 152 qualitative comparison with existing knowledge of the anatomical distribution of structural aberrations, and in a quantitative, predictive context. Next, we applied the pipeline to a large, 153 longitudinal dataset of MCI patients to create individual morphological records, a proposed data 154 format for tracking and visualizing disease progression. Finally, we investigated the clinical 155 utility of these records for stratifying patients, both in terms of their specific clinical profile, and 156 progression of the disease. To facilitate reproducibility and improve the translational value of our 157 work, the trained models and the complete explainable pipeline is made accessible on GitHub. 158



159

160 *Figure 1: Overview of the modelling process.* The modelling process consisted of four

161 sequential steps. First, we fit multiple Simple Fully Convolutional Networks to classify dementia

162 patients and healthy controls based on structural MRIs. Then we applied the best models to

163 generate out-of-sample predictions and relevance maps for all participants. Next, we validated

- 164 *the relevance maps against existing knowledge using a meta-analysis to generate a statistical*
- 165 reference map. Finally, we employed the full pipeline in an exploratory analysis to stratify
- 166 patients with mild cognitive impairment (MCI).

167 **Results**

We compiled MRI data from multiple sources (Supplementary Table 1) into a dataset of 168 heterogeneous dementia patients (n=854, age range=47-95, 47% females, Table 1) based on 169 various diagnoses (Probable AD, vascular dementia, other/unspecified dementia) and diagnostic 170 criteria for inclusion (Supplementary Table 2), and a set of controls strictly matched on site, age, 171 and sex of equal size. We trained multiple CNNs to differentiate between the groups, employing 172 a cross-validation approach utilizing all available timepoints for participants in three training 173 folds and a single randomly selected timepoint for participants in separate validation and test 174 folds. When stacking the out-of-sample predictions for all participants from all folds together 175 (n=1708), for each fold using the model with the best validation performance, we observed 176 satisfactory discrimination with a combined area under the receiver operating characteristics 177 curve (AUC) of 0.908 (0.904-0.920 split across folds, Supplementary Figure 1), and an accuracy 178 of 84.95% (83.04%-87.13%, Supplementary Table 3). This is slightly below with what is 179 180 commonly achieved in similar studies classifying a specific subtype (typically AD) in a single dataset 28. 181

CNN training and cross-validation						
Cohort	Participants	Mean age (±std)	Sex (F/M)			
Healthy controls	854	75.13 <u>+</u> 7.81	401/453			
Dementia patients	854	74.82 <u>+</u> 7.84	401/453			
Total	1708	74.98 <u>+</u> 7.82	802/906			
	Downstream pro	gnostic and correlational ana	lyses			
Improved MCI	80	71.18 <u>+</u> 8.14	37/43			
Stable MCI	754	74.63 <u>+</u> 7.66	324/430			
Progressive MCI	304	75.60±7.46	124/180			
Total	1138	74.67 <u>+</u> 7.73	485/653			

Table 1: Cohorts. Key characteristics of the cohorts used for training and testing the models,
and further exploratory analyses.

185

Relevance maps highlight predictive brain regions in individuals with dementia 186 Based on the classifiers with the highest AUCs in the validation sets, we built an explainable 187 pipeline for dementia prediction, $LRP_{dementia}$, using composite LRP ⁴⁴, and a strategy to 188 prioritize regions of the brain that contributed positively towards a prediction of dementia in the 189 explanations. Using this pipeline, we computed out-of-sample relevance maps for all participants 190 by applying the model for which the participant was unseen. Qualitatively, these maps 191 corroborated known anatomical locations with structural aberrations in dementia, while still 192 allowing for inter-individual variation (Supplementary Figure 2). We confirmed this apparent 193 corroboration quantitatively by comparing a voxel-wise average map $\overline{R}_{dementia}$ (Supplementary 194 Figure 3), containing positive relevance from all correctly predicted dementia patients, with a 195 statistical reference map G (Supplementary Figure 4) from an activation likelihood estimation 196 (ALE) meta-analysis ⁴⁵, methodology established by an earlier study ⁴⁰. For sanity checks, we 197 also computed average maps from three alternative pipelines, \overline{R}_{sex} , $\overline{R}_{randomized weights}$ and 198 $\overline{R}_{randomized images}$. The comparisons with the reference map were done by binarizing the maps 199 on both sides of the comparison at various thresholds and measuring the Dice overlap (Figure 200 2a). For the three alternative pipelines the amount of overlap decreased monotonically as the 201 binarization threshold rose (Figure 2b), whereas for $\overline{R}_{dementia}$ it stabilized as the maps grew 202 203 sparser, indicating its higher similarity with G. This effect was reaffirmed by a normalized crosscorrelation ⁴⁶ of 0.64 for $\overline{R}_{dementia}$, compared to 0.41, 0.40 and 0.12 of \overline{R}_{sex} , 204 $\overline{R}_{randomized weights}$ and $\overline{R}_{randomized images}$ respectively. In addition, we performed a region-205 wise, qualitative comparison of $\overline{R}_{dementia}$ and G, also yielding general agreement (Figure 2c), 206 with the most important regions in both maps being the nucleus accumbens, the amygdala, and 207 the parahippocampal gyrus. Next, we tested the importance of the detected regions in a 208 predictive context, by applying an iterative mask-and-predict procedure. For each participant, we 209 produced a baseline dementia-prediction \hat{y}_0 and relevance map R_{task} for each pipeline LRP_{task} . 210

- 211 We then iteratively masked out the most important regions of the image according to the
- relevance map and recorded how the prediction changed as a function of the occlusion (Figure

- 213 2d). Using only true positives, the predictions should ideally start out at approximately 1.0
- 214 (empirically found to be 0.89 on average) and trend towards 0.5 (random prediction) as a larger
- 215 proportion of the image is occluded. The rate of decline is indicative of whether the masked
- regions contain information essential for the classifier to classify the image correctly. Over 20
- 217 iterations we observed that the predictions based on maps from both $LRP_{dementia}$, LRP_{sex} and
- 218 LRP_{randomized weights} decreased, but LRP_{dementia} at a distinctly steeper rate than the rest
- 219 (Figure 2d). To quantify this observation we calculated an area over the perturbation curve
- 220 (AOPC) of 0.231, 0.009, -0.001 and 0.002 for *LRP*_{dementia}, *LRP*_{sex}, *LRP*_{randomized images},
- 221 *LRP_{randomized weights}* respectively. Taken together, these results demonstrate that our pipeline
- 222 generates maps with relevance in brain regions associated with changes in dementia.
- 223



Figure 2: Validation of relevance maps from the dementia pipeline compared with three alternative pipelines. a Visualization of the comparison between the binarized average relevance

map $\overline{R}_{dementia}$ from the dementia-pipeline and the binarized statistical reference map G from 228 GingerALE, at different thresholds for binarization. **b** Overlap between the four average 229 relevance maps \overline{R} from our four pipelines and G as a function of the binarization threshold. The 230 numbers in the legend denote the normalized Cross Correlation (nCC) for each pipeline c Mean 231 232 voxel-wise activation in $R_{dementia}$ and G, grouped by brain region. d Average participant-wise prediction from the dementia model after iteratively masking out regions of the image according 233 to relevance maps from the four pipelines. Area over the permutation curve (AOPC) for the 234 dementia map is indicated by the shaded area and denoted in the legend for all pipelines. 235

236

237 Output from the explainable dementia pipeline has prognostic value for MCI

238 patients

For the MCI patients (n=1256, timepoints=6448), previously unseen by all models, we built an 239 averaging ensemble to procure a singular out-of-sample prediction and relevance map per patient 240 per timepoint. Put together, we let this represent a morphological record (illustrated in Figure 4) 241 visualizing the absolute quantity (indicated by the prediction) and location (indicated by the 242 relevance map) of dementia-related pathology detected by the models over time. Qualitatively, 243 both predictions and maps were relatively stable within a participant over time, while allowing 244 enough variation to compose what resembled a trajectory. To investigate the prognostic value of 245 our proposed morphological records we divided the MCI patients into three subgroups based on 246 247 their trajectories in the follow-up period: those who saw improvement of their condition (n=80), those with a stable diagnosis throughout (sMCI, n=754), and those who progressed into dementia 248 249 (pMCI, n=304). The remaining (n=118) had either a non-MCI diagnosis at the first timepoint, or a more complex diagnostic trajectory (e.g MCI -> AD -> CN) and were excluded from 250 251 subsequent analyses. We observed that the predictions in the first group were generally very low (mean $\hat{y} = 0.13$, Supplementary Figure 5a), indicating that the models detected little, if any, 252 evidence of dementia in these participants. For the stable patients the mean prediction was higher 253 (mean $\hat{y} = 0.33$), but still below the classification threshold of 0.5, whereas in the progressive 254 group the model predicted the average patient to already have dementia (mean $\hat{y} = 0.72$). 255 256 Importantly, this was also true when considering only timepoints before these patients received the clinical diagnosis (mean $\hat{y} = 0.65$, Supplementary Figure 5b), suggesting that the model 257

found evidence of the disorder before the clinical symptoms surpassed the diagnostic threshold. 258 To formally delineate the differences in predictions leading up to the potential diagnosis, we 259 combined the improving and stable patients into a non-progressive group (nMCI, n=834), and 260 sampled patients to match the progressive group based on their visiting histories, leading up to a 261 terminal diagnosis timepoint (or a constructed non-diagnosis timepoint in the non-progressive 262 group). In this matched dataset (n=550) we applied a linear mixed model controlling for age and 263 sex and observed that the group difference was even greater than what we previously observed (β 264 = 0.47, p = 6.05 $\times 10^{-71}$, Figure 3a, Supplementary Table 4). Furthermore, we observed a 265 significant difference in longitudinal slopes ($\beta = 0.05$ increase in prediction per year, p = 266 8.14×10^{-17}) indicating a greater rate of brain change detected by the model in those who 267 would be diagnosed with dementia at a later point in time. 268

269

The large group differences in the dementia predictions leading up to a potential diagnosis 270 suggests this as a biomarker with innate prognostic value, yet the most salient part of our 271 morphological records were the relevance maps. Thus, we performed exploratory analyses based 272 273 on these to further differentiate the non-progressive and progressive groups and characterize both inter- and intra-group heterogeneity. However, given the high dimensionality of the maps and the 274 relatively small number of patients, we first applied a principal component analysis (PCA) to 275 relevance maps from all MCI patients, effectively compressing their information content into a 276 smaller set of characteristic variables encoding facets of the maps, enabling the subsequent 277 278 analyses. We retained the 64 components that explained the largest amount of variance and observed that they qualitatively clustered into three overarching categories. The first component 279 was a generic component detecting general presence of relevance, resembling the average map 280 from dementia patients, and thus made up a cluster by itself. The next cluster was comprised of 281 the subsequent three components that captured high level, abstract patterns of relevance, namely 282 differences in lateralization, along the sagittal axis and in subcortical regions (Figure 3b). The 283 final cluster consisted of the remaining 60 components that captured specific, intricate patterns of 284 presence/non-presence of relevance in regions revealed in the preceding analyses 285 (Supplementary Figure 6). To investigate the potential of using the relevance maps for prognosis, 286 we first performed a survival analysis using a Cox proportional hazards model where getting a 287 diagnosis was considered the terminal event. 288







303 *composite language (PHC_LAN) and executive function (PHC_EXF) scores from the ADSP*

304 *Phenotype Harmonization Consortium, total score from the Functional Activities Questionnaire*

- 305 (FAQTOTAL), composite executive function score from UW Neuropsych Summary Scores
- 306 (ADNI_EF), clinical evaluation of impairment related to judgement and problem solving
- 307 (CDJUDGE) from the Clinical Dementia Rating, and an overall measure of cognition from the
- 308 Mini-Mental State Examination (MMSCORE, commonly referred to as MMSE).

309 Specifically, we modelled the fraction of the population without a diagnosis as a function of age and used the subject-wise loadings of c_t as predictors. After Benjamini-Hochberg correction, 37 310 311 of these components were significantly associated with staying undiagnosed (Figure 3c and Supplementary Table 5). However, we observed a correlation between the singular dementia 312 prediction \hat{y} and the absolute magnitudes of these components (Supplementary Figure 7), 313 indicating that the associations in the survival analysis could be induced by differences in the 314 prediction rather than variability in the relevance maps. To mitigate this concern, we fit an 315 equivalent model while stratifying on \hat{y} , observing that 29 associations remained significant, and 316 that all coefficients had the same sign. Nonetheless, this analysis did not account for the 317 318 predictions and relevance maps changing within a participant over time, so we reframed the question in a purely predictive setting, constructed to bear resemblance to a clinical scenario, 319 320 using the same participants (nMCI=834, pMCI=304, total n=1138). For each MCI patient p at each timepoint t we asked whether we were able to predict, at yearly intervals γ up to five years 321 into the future, whether p had progressed into dementia, using information from $LRP_{dementia}$ 322 available at t. Importantly, all timepoints for all these participants were unseen by the dementia-323 324 model, yielding out of sample predictions and relevance maps from LRP_{dementia}, and we employed nested cross-validation to ensure the progression predictions were also out-of-sample. 325 First, we fit a baseline model \mathcal{M}_{hase} with age and sex as predictors, showing no predictive 326 efficacy at any timepoint (all AUCs ≈ 0.5 , Supplementary Table 6), indicating that the dataset 327 was not biased with respect to these variables. When adding the prediction from the dementia 328 329 model \hat{y}_t as a predictor in model \mathcal{M}_{pred} we saw large improvements in prognostic efficacy at all 330 yearly intervals, culminating with a fold-wise mean AUC of 0.889 after five years (Figure 3d). In the final model, \mathcal{M}_{comp} , also including the component vector c_t as predictors, we saw further 331 improvements for all years, peaking at 0.903 after five years (p = 0.035 when compared to 332

- 333 \mathcal{M}_{pred} in a Wilcoxon signed-rank test across the outer folds). Overall, our best performing
- model predicted progression to dementia after five years with an AUC of 0.903, an accuracy of
- 84.1%, a positive predicted value of 0.92, a sensitivity of 0.82 and a specificity of 0.86 (Table 2).
- 336

Model	AUC	Balanced	PPV	Sensitivity	Specificity	
		accuracy				
\mathcal{M}_{base}	0.515	51.05%	0.14	0.09	0.93	
\mathcal{M}_{pred}	0.889	83.61%	0.91	0.83	0.84	
\mathcal{M}_{comp}	0.903	84.1%	0.92	0.82	0.86	

337Table 2: Predictive performance of the three models predicting progression five years into the338future. The baseline model \mathcal{M}_{base} used only age and sex as covariates. \mathcal{M}_{pred} also added the339prediction from the dementia model at the current timepoint as a predictor, while \mathcal{M}_{comp} 340additionally included the component vector c_t encoding information from the relevance maps.341

Facets of the relevance maps are associated with cognitive impairments indistinct domains

Finally, we tested whether common features found in the relevance maps, represented by the 344 PCA component, were correlated with impairments in distinct cognitive and functional domains. 345 We extracted 17 summary measures from 7 neuropsychological tests (Supplementary Table 7 346 and 8), performed approximately at the same time as an MRI examination, and tested for 347 associations with the subject-wise loadings of c_t in 733 MCI patients using linear models. After 348 FDR correction, while correcting for age, sex and \hat{y} , we found 48 significant correlations 349 between 18 unique components and 14 of the cognitive measures (Figure 3e). Component 30 and 350 the aggregate score from the Functional Activities Questionnaire (FAQTOTAL) had the highest 351 352 number of significant hits among the components and measures respectively, both with six passing the threshold. Most importantly, the components showed distinct patterns of associations 353 with the different cognitive measures. To ensure the significant associations were not driven by 354 collinearity between components c_i and \hat{y} , we ran an equivalent analysis without including \hat{y} as a 355 predictor, observing that only 5/48 of the previously significant hits had coefficients with the 356 opposite sign. To summarize, the spatial features captured in our relevance maps, and 357 358 subsequently in our component vectors, were associated with distinct patterns of performance on

- 359 neuropsychological tests relevant for characterizing phenotypic heterogeneity in dementia
- 360 patients (Supplementary Figure 8).



362

Figure 4: A visualization of the proposed morphological record for a randomly selected 363 progressive MCI patient that was held out of all models and analyses. a The top half shows the 364 prediction from the dementia model at each visit, while the bottom part displays the relevance 365 map underlying the prediction. The opaque sections (including c, d, and e) contain information 366 accessible at the imagined current timepoint (22.02.07) to support a clinician in a diagnostic 367 procedure. The angle () represents the change in dementia prediction per year based on the 368 first two visits. **b** Translucent regions reveal the morphological record for the remaining follow 369 ups in the dataset, thus depicting the future. The ground truth diagnostic trajectory is encoded by 370

- 371 the colour of the markers. **c** Predicted probabilities of progression at future follow-ups based on
- 372 the prediction and relevance map at the current timepoint. **d** Survival curve of the patient
- 373 *compared to the average MCI patient calculated from the prediction and relevance map. The*
- 374 marker indicates the location of the patient at the current timepoint. *e* A list of cognitive domains
- 375 where the patient is predicted to significantly differ from the average based on the prediction
- 376 *and relevance map.*
- 377

378 Discussion

Given the huge burden of disease and expected increase in prevalence, innovative technological 379 solutions for clinical decision making in dementia diagnostics and prognostics is urgently 380 needed. Although commonly referred to as a homogenous condition or split into a few subtypes 381 based on aetiology or pathophysiology¹⁷, dementia patients exhibit unique and complex 382 deficiencies, disease trajectories, and cognitive deficits. To explore the potential of brain MRI 383 and XAI to characterize heterogeneity in the brain underpinnings of dementia, we trained neural 384 networks to differentiate dementia patients from healthy individuals, and derived relevance maps 385 using Layerwise Relevance Propagation to explain the individual-level decisions of the classifier. 386 The relevance maps were specific to the individual, spanned regions that were predictive of 387 dementia and corroborated existing knowledge of the anatomical distribution of structural 388 aberrations. In a cohort of MCI patients, it enabled characterization and differentiation of 389 390 individual-level disease manifestations and trajectories linked to cognitive performance in multiple domains. While further validations in clinical contexts are needed, our XAI pipeline for 391 dementia demonstrates how advanced predictive technology can be employed by clinicians to 392 monitor and characterize disease development for individual patients. 393

394

There is a multitude of XAI techniques available for explaining the decisions of an image 395 classifier, many of which have yielded promising results for dementia classification ³⁸. We 396 employed LRP due to its straightforward interpretation as well as earlier studies indicating 397 robustness ⁴⁷ and specificity ⁴², properties we consider integral in a clinical decision support 398 system. But while procuring explanations that are *ipso facto* meaningful is an important step 399 towards adoption of AI in clinical neuroimaging, it is not in itself sufficient. There is a host of 400 predictive models that are trivially explainable, but not understandable ⁴⁸, and there is genuine 401 concern that XAI will lead to another level of systems that are formally well-defined, but opaque 402 and obscure, and thus practically useless ⁴⁹. Thus, empirical explorations are imperative to 403 investigate the nature of these explanations, examine how they may be useful and build essential 404 trust 50 . In our validation, we observed that the explanatory maps produced by the dementia 405 pipeline were more predictive and showed distinctly more agreement with existing knowledge of 406 407 pathology than those produced by the three alternative pipelines. Given limitations that have been exposed in such methods earlier 51,52 these validations are crucial, and observing that our 408

results both corroborate earlier evidence ⁴⁰ and extend upon it, provides confidence that the
explanations derived from the model are meaningful. However, we emphasize that the ultimate
validation should happen in actual implementations of the technology in end-user systems, with
clinical personnel applying it in clinical scenarios on realistic data.

413

We continued beyond validating the relevance maps by proposing them as a potential epistemic 414 and clinical tool to characterize individual facets of dementia. To this end, we explored if the 415 maps contributed to predicting imminent progression from MCI to dementia, and correlated them 416 with different cognitive measures, extending upon the current literature ³⁸. In both analyses we 417 found evidence, although modest, that the maps are informative beyond the predictions of the 418 model. To illustrate the potential of the pipeline for clinical decision making we compiled its 419 output into a proposed morphological record (visualized for a single patient in Figure 4) that can 420 help clinicians localize morphological abnormalities during a diagnostic process. Identifying 421 subtle pathophysiology through deep phenotyping could have a huge potential for charting the 422 heterogeneity of dementia, providing precise biological targets to guide future research. 423 Furthermore, for the individual patient, it can support personalized diagnosis to identify 424 appropriate disease-modifying treatments, and in the future, hopefully, accurate therapeutic 425 interventions. 426

427

428 The regions with the highest density of relevance in our maps were the nucleus accumbens, amygdala and the parahippocampal gyrus, all of which are strongly affected in dementia 53-55. 429 While the two latter corroborate the established involvement of the medial temporal lobe 56 it is 430 surprising that the hippocampus does not appear in our analyses, as it has frequently in similar 431 studies ^{38,41,42}. While this could be caused by actual localization of pathology ⁵⁷ we consider it 432 more likely to be related to the internal machinery of the model. Specifically, the CNN relies on 433 spatial context to identify brain regions before assessing their integrity, utilizing filters that span 434 areas of the image larger than those containing the region itself. In the backwards pass, LRP uses 435 these filters, and thus the localization of relevance is not necessarily voxel precise. Furthermore, 436 we believe the model broadly can be seen as an atrophy detector, which necessarily entails 437 looking for gaps surrounding regions instead of directly at the regions themselves. Therefore, 438

while the relevance maps provide important information, they depend on contextual informationand thus rely on interpretation from clinicians to maximize their utility in clinical practice.

441

We focused our analyses mainly on the relevance maps, but the results with largest, immediate, 442 potential for clinical utility were the predictions from the dementia classifier. Other studies have 443 shown the efficacy of machine learning models in differentiating dementia patients and healthy 444 controls ²⁸, but it is intriguing that we see a large discrepancy in the predictions of the 445 progressive and non-progressive MCI patients many years before the dementia diagnosis is 446 given. This corroborates findings from theory-driven studies ⁵⁸ and a recent deep learning study 447 ²⁷, implying detectable structural brain changes many years before the clinical diagnosis is given. 448 This gives hope for advanced technology to contribute to early detection and diagnosis through 449 MRI based risk scores, in our case supported by a visual explanation. If curative treatments 450 prove efficacious and become accessible, early identification of eligible patients could be 451 imperative ⁵⁹. Furthermore, timely access to interventions have shown efficiency in slowing the 452 progress of cognitive decline ⁶⁰, in addition to improving the quality of life for those afflicted and 453 their caregivers ^{26,61}. Widely accessible technology that allows for early detection with high 454 precision could play a key role in the collective response to the impending surge of patients and 455 provide an early window of opportunity for more effective treatments. 456

457

458 While our results show a great potential for explainable AI, and particularly LRP, as a translational technology to detect and characterize dementia, there are limitations to our study. 459 First, there are technical caveats to be aware of. Most importantly, there is an absolute 460 dependence between the predictions of our model and the relevance maps. In our case, when we 461 462 qualitatively assessed the relevance maps of the false negatives, they were indistinguishable from the true negatives. This emphasizes the fact that when the model is wrong, this is not evident 463 from the explanations. Next, while the maps contain information sufficient to explain the 464 prediction, they are not necessarily complete. Thus, they don't contain all evidence in the MRI 465 pointing towards a diagnosis, a property which could prove essential for personalization. We 466 have addressed this problem through pragmatic solutions, namely ensembling and targeted 467 augmentations, but theoretical development of the core methodology might be necessary to 468 theoretically guarantee complete maps. Beyond the fundamental aspects of LRP, there are 469

weaknesses to the present study that should be acknowledged. First, the dataset with dementia 470 patients portrayed as heterogeneous mostly consists of ADNI and OASIS data, and thus patients 471 472 with a probable AD diagnosis (although clinically determined). Thus, while we consider it likely, it is not necessarily true that the dimension of variability spanning from healthy controls to 473 dementia patients portrayed by our model has the expressive power to extrapolate to other 474 aetiologies. To overcome this in actual clinical implementations, we encourage the use of 475 datasets that are organically collected from subsets of the population that are experiencing early 476 cognitive impairments, for instance from memory clinics. Furthermore, it is not trivial to 477 determine whether a clinical, broad, dementia-label is an ideal predictive target for models in 478 clinical scenarios. Both ADNI and AIBL contain rich biomarker information with multiple 479 variables known to be associated with dementia, such as amyloid positivity. It would be 480 intriguing to see studies methodologically similar to ours with a biological predictive target, and 481 we encourage investigations into whether this supports and complements the results we have 482 observed here. Another limitation with the present study is out-of-sample generalization, 483 especially related to scanners and acquisition protocols. Although we utilize data from many 484 sites, which we have earlier shown to somewhat address this problem ⁶², in combination with 485 transfer learning, we did not explicitly test this by e.g., leaving sites out for validation. Again, we 486 487 advise that clinical implementations should be based on realistic data, and thus at least be finetuned towards data coming from the relevant site, scanner, and protocol implemented in the 488 clinic ⁶³. This also includes training models with class frequencies matching those observed in 489 clinical settings, instead of naively balancing classes as we have done here. Next, we want to 490 491 explicitly mention the cyclicality of our mask-and-predict validation. In a sense it trivially follows that regions that are considered important by a model are also the ones that are driving 492 493 the predictions, and thus it is no surprise that the relevance maps coming from the dementia model are more important to the dementia model than the maps coming from e.g., the sex model. 494 We addressed this by alternating the models for test and validation, but fully avoiding this 495 circularity would require disjunct datasets, and more and larger cohorts. Finally, we highlight the 496 497 potential drawbacks of including the improving MCI patients alongside the stable in the progression models. We believe this accurately depicts a realistic clinical scenario, where 498 diagnostic and prognostic procedures happen based on currently available clinical information. 499 500 However, that these patients improve could indicate that their condition is not caused by stable

biological aberrations. This could oversimplify the subsequent predictive task, inflating our 501 performance measures. In summary, the predictive value we observed for the individual patient 502 503 must be interpreted with caution. However, our extensive validation approach as well as our thorough explanation of the method and its limitations, and training on large datasets, provide a 504 first step towards making explainable AI relevant for clinical decision support in neurological 505 disorders. Nonetheless, it also reveals a complicated balance between validating against existing 506 knowledge and allowing for new discoveries. In our case, confirming whether small details 507 revealed in the relevance maps are important aspects of individualization or simply intra-508 individual noise requires datasets with a label-resolution beyond what currently exists. Thus, we 509 reiterate our belief that the continuation of our work should happen at the intersection between 510 clinical practice and research ⁶⁴, by continuously collecting and labelling data to develop and 511 validate technology in realistic settings. 512

513

To conclude, while there are still challenges to overcome, our study provides an empirical 514 foundation and a roadmap for implementations of brain MRI based explainable AI in 515 516 personalized clinical decision support systems. Specifically, we show that deep neural networks trained on a heterogenous set of brain MRI scans can predict dementia, and that their predictions 517 518 can be made human interpretable. Furthermore, our pipeline allows us to reason about structural brain aberrations in individuals showing early signs of cognitive impairment by providing 519 520 personalized characterizations which can subsequently be used for precise phenotyping and prognosis, thus fulfilling a realistic clinical purpose. 521

522 Materials and Methods

523 Data

All data used in the present study have been obtained from previously published studies which have been approved by their respective institutional review board or relevant research ethics committee.

527

528 To train the dementia models we compiled a case-control dataset from seven different sources

529 (Supplementary Table 1), consisting of patients with a dementia diagnosis and healthy controls

from the same scanning sites. Because of the different diagnostic criteria used in the original

datasets we applied different rules to achieve a singular, heterogeneous dementia label 531 (Supplementary Table 2). We extracted all participants with a dementia-diagnosis at all 532 533 timepoints to comprise the patient group (n=854). Then, for each unique proxy site (In ADNI, due to the large number of scanners and acquisition protocols, and the work put into unifying 534 them, we used field strength as a proxy for site), sex, and age-bin spanning 10 years, we sampled 535 an equal number of healthy controls to form the matched control set (total n=1708, Table 1). 536 Lastly, before modelling, we split the data into five equally sized folds stratified on diagnosis, 537 site, sex, and age, such that all timepoints for a single participant resided in the same fold. 538 539

For the MCI dataset we started with all participants from all ADNI waves with an MCI diagnosis 540 (subjective memory complaint, MMSE between 24 and 30, CDR>0.5 with memory box>0.5, 541 Weschler Memory Scale-Revised <9 for 16 years of education, <5 for 8-15 years of education 542 and <3 for 0-7 years of education)⁶⁵, on at least one timepoint. These were 12661 images from 543 6448 visits for 1256 participants, none of which were used for model training. This selection 544 criterion ensured all participants had an MCI diagnosis at one point in time, though it did not 545 limit us to only those timepoints. Thus, in addition to those with a consistent, stable, MCI 546 diagnosis (sMCI), we had a variety of diagnostic trajectories, including those transitioning from 547 normal cognition to MCI, MCI to AD (pMCI) and various other combinations. Before the 548 subsequent analyses we discarded all participants without an MCI diagnosis initially, and 549 550 everyone with ambiguous trajectories (e.g. MCI->CN->AD), leaving 5607 visits from 1138 participants. 551

552

From these two datasets we extracted T1-weighted structural MRI data for each participant at each timepoint to use as inputs for the subsequent predictive models. Prior to modelling, the raw images were minimally processed using a previously developed pipeline ²/21/2024 12:12:00 PM relying on FreeSurfer v5.3 and FSL v6.0 ⁶⁶ to perform skullstripping ⁶⁷ and linear registration to MNI152-space ⁶⁸ with six degrees of freedom. Consequently, the processed images consisted of normalized voxel values from the raw images, registered to a common spatial template and contained minimal non-brain tissue.

561 Modelling

All dementia models were variants of the PAC2019-winning simple fully convolutional network 562 (SFCN) architecture ^{69,70}, modified to have a single output neuron with a sigmoid activation. The 563 564 architecture is a simple, VGG-like convolutional neural network with 6 convolutional blocks and approximately 3 million parameters. We initialized the model with weights from a publicly 565 accessible brain age model previously shown to have superior generalization capabilities when 566 dealing with unseen scanning sites and protocols ⁶². The models were trained on a single Nvidia 567 A100 GPU with 40GB of memory, Tensorflow 2.6⁷¹ through the Keras interface ⁷². We used a 568 vanilla stochastic gradient descent (SGD) optimizer with a learning rate defined by the 569 hyperparameter settings (see next section), optimizing the binary cross-entropy loss. All models 570 ran for 160 epochs with a batch size of 6, and for each run the epoch with the lowest validation 571 loss was chosen. Varying slightly depending on the hyperparameters, a single model trained in 572 approximately 4 hours. 573

574

For each hold-out test fold we trained models on three of the remaining folds and validated on 575 the fourth, akin to a cross-validation with an additional out-of-sample test set, to achieve out-of-576 sample predictions for all 1708 participants while allowing for hyperparameter tuning. The 577 hyperparameters we optimized were dropout $d \in \{0.25, 0.5\}$ and weight decay $w \in$ 578 $\{10^{-2}, 10^{-3}\}$. Additionally, we tested stepwise, one-cycle and multi-cycle learning rate 579 schedules and a light and a heavy augmenter. Initial values for the learning rate were set 580 manually based on a learning rate sweep 73 , though kept conservative to preserve the learned 581 features from the pretraining. The hyperparameter search was implemented as a naive grid-582 search over the total 24 different configurations (Supplementary Figure 9). We selected the 583 model procuring the best AUC in the validation set to produce out-of-sample predictions for the 584 outer hold-out fold. In the final evaluation of the models, we compiled predictions for all 585 participants, for each using the model where they belonged to the hold-out test set. Our main 586 method for measuring performance was the AUC, but we also report accuracy, which, due to our 587 matching procedure, is equivalent to balanced accuracy. 588

590 Relevance maps

We built a pipeline LRP_{dementia} for generating relevance maps by implementing LRP (Bach et 591 al., 2015) on top of the trained classifier. LRP is a technique for explaining single decisions 592 made by the model, and thus, when running the pipeline on input X a relevance map R is 593 generated alongside the prediction \hat{y} . *R* is a three-dimensional volume, representing a visual 594 explanation for \hat{y} , where each voxel $r_{i,j,k} \in R$ has a spatial position i, j, k corresponding to the 595 location of an input voxel $x_{i,i,k} \in X$. Furthermore, the intensity of $r_{i,i,k}$ can be directly 596 interpreted as how much voxel $x_{i,i,k}$ contributes to \hat{y} , such that $\sum_{r \in R} r = \hat{y}$. In the original LRP-597 formulation, relevance r is propagated backwards between subsequent layers Z_l and Z_{l+1} 598 according to the relative contribution of one artificial neuron $a_m \in Z_l$ in the first layer on 599 relevance in all artificial neurons $a_n \in Z_{l+1}$ in the following layer, 600

601

$$r(a_m) = \sum_j \frac{a_m w_{mn}}{\sum_o a_o w_{on}} r(a_n),$$

603

where w_{mn} denotes the weight between a_m and a_n . We controlled the influence of different 604 aspects of the explanations using a composite LRP strategy ⁴⁴, combining different formulations 605 of the LRP-formula for the different layers in the model to enhance specific aspects of the 606 relevance maps. Specifically, we employed a combination of alpha-beta and epsilon rules that 607 have previously shown to produce meaningful results for dementia-classifiers ^{41,42}, described in 608 detail in the Supplementary Methods. The resulting relevance maps produced by the pipeline 609 were full brain volumes with the same dimensionality as the MRI data (167x212x160 voxels) 610 611 containing mostly (see below) positive relevance.

612

Notation-wise we generally consider the relevance map R(X) for an image X to be a function of the model m_{task} , where task indicates which task the model was trained for, the LRP strategy LRP_{composite} and the image X,

- 616
- 617 $R(X) = f(m_{task}, LRP_{composite}, X).$
- 618

619	Because the composite LRP strategy described above is kept fixed in our pipeline, we contract
620	this to
621	
622	$R(X) = f(m_{task}, X).$
623	
624	Furthermore, we let the model-specifier task annotate the map for a further simplification,
625	
626	$R_{task}(X) = f(X).$
627	
628	Thus, LRP_{task} is used to annotate the full pipeline for a given task, while $R_{task}(X)$ denotes a
629	single relevance map generated by this pipeline for image X . When the task is given by the
630	context, we sometimes simplify this further to $R(X)$, and when a general image is considered, we
631	simply use R to denote its relevance map.
632	
633	While we generally discuss our pipeline as a singular one, there were in reality five
634	approximately equivalent pipelines (corresponding to the models trained for the five test folds),
635	and which one is used depends on what image was used as input. Specifically, for each
636	participant diagnosed with dementia, the pipeline is chosen where the participant was part of the
637	hold-out test set while training the model, and both the relevance maps and the predictions are
638	thus always out-of-sample. For participants used in the MCI analysis, which are all out-of-
639	sample for all models, we created an ensemble by averaging the predictions and the voxel-wise
640	relevance across all models.
641	
642	Before implementing the LRP procedure we made two slight modifications to the models to
643	facilitate the backwards relevance propagation, both leaving the functional interface of the model
644	unchanged. First, we removed the sigmoid activation in the final layer, so that the output of the

model changed from a bounded continuous variable $\hat{y} \in [0, 1]$ to an unbounded prediction

prediction of $\hat{y} = 0.5$, and thus $\hat{y}_{\sigma} < 0$ means that the model predicts control status for the

 $\hat{y}_{\sigma} \in [-\infty, \infty]$. In this space a raw prediction of $\hat{y}_{\sigma} = 0$ is equivalent to a sigmoid-transformed

given participant, and oppositely $\hat{y}_{\sigma} > 0$ implies that the model predicts a dementia diagnosis.

Furthermore, this means that all positive relevance $r \in R$, r > 0 can be interpreted as visual

645

646

647

648

evidence in favour of a dementia diagnosis. Secondly, we modified the model by fusing all batch
normalization layers with their preceding convolutional layers, adjusting their weights and biases
to match the shift and scaling previously performed by the normalization layer ^{74,75}.

653

After generation, the relevance maps are in the same stereotaxic space as their corresponding, 654 linearly registered, input MRIs. To ensure intra-individual comparisons were done in the same 655 space we non-linearly registered the maps to MNI152- space before subsequent statistical 656 analyses were run. First, we registered the preprocessed MRIs X used as inputs to the 1mm 657 MNI152 template packaged with FSL using fnirt with splineorder=2. We then applied the 658 transformation computed for X to R(X) using applywarp. We also restrained our relevance maps 659 to contain strictly positive relevance, evidence in favour of a dementia prediction, by clipping 660 661 them to a minimum value of 0. Furthermore, to remove edge-effects from our analyses, we enforce that there is no relevance in non-brain tissue by nullifying all relevance outside the brain: 662 663

664

$$\forall (i,j,k) \big[x_{i,j,k} = 0 \Rightarrow r_{i,j,k} = 0 \big].$$

665

All visualized relevance maps are plotted after non-linear registration, overlayed on the MNI152template. As the maps are three-dimensional, we generally plot a collection of distributed axial slices. The relevance is coloured by the nibabel v3.2.2 76 cold_hot colourmap. Since the absolute relevance values vary between maps, all maps are normalized to the intensity range [0, 1] in the visualizations.

671

Validating the relevance maps

Earlier studies have shown that interpretability techniques in general are prone to generate visual explanations that do not capture salient parts of the input ^{51,52}. To investigate the extent of this for our pipeline $LRP_{dementia}$ we employed two analyses to assess the sanity of the relevance maps. The first was an established task-specific technique comparing the relevance maps to existing knowledge of the pathology of dementia ⁴⁰. The second was a purely quantitative analysis examining how important the regions found by the pipeline are for the dementia prediction \hat{y} . In both cases we contrasted the relevance maps generated from the main pipeline with three

91592; this version posted February 22, 2024. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/20 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

alternative pipelines representing variants of a null hypothesis, all expected to produce relevance 680 maps with no significant association to dementia. 681

682

LRP_{random images} represents the simplest alternative pipeline, and is built around the dementia-683 model, but with an additional preprocessing step scrambling the input, 684

685

 $R_{random images}(X) = R_{dementia}(X)$, where $\mathcal{X} = \mathcal{N}(\bar{X}, \sigma_X).$ 687

688

LRP_{random images} is expected to generated relevance maps where the relevance is evenly 689 distributed across the entire image. In the next pipeline $LRP_{random weights}$ we replaced the 690 dementia-model with a model with random weights, 691

692

 $R_{random weights}(X) = R(m_{\theta}, X).$

694

 m_{θ} has not been trained for any task, and thus has random weights initialized by the default 695 Keras "Glorot Uniform" weight-initializer. This pipeline is expected to produce relevance maps 696 which correlate with the raw voxel intensities, e.g. high intensity in the input should entail more 697 (absolute) relevance, thereby reflecting aspects of morphology. The final and most realistic 698 alternative pipeline was LRPsex, where we replaced the dementia-model with a binary sex-699 classifier, 700

701

702

- $R_{sar}(X) = R(m_{sar}, X).$
- 703

The sex-classifier was trained to differentiate males from females in one of the splits from the 704 705 dementia-dataset, achieving an out-of-sample AUC of 0.956 and a balanced accuracy of 89.40%. We did not do any hyperparameter optimization for this model but used the best configuration 706 707 from the dementia cross-validation in the same fold. The heatmaps from this pipeline should reflect regions where there is intra-individual variation in morphology, which are predictive of 708 709 sex but with minimal association with dementia.

711	As a proxy for existing knowledge in the literature we performed an ALE meta-analysis using
712	Sleuth v3.0.4 77 and GingerALE v3.0.2 45 . We used Sleuth to search for relevant articles with the
713	query
714	
715	Imaging Modality is MRI
716	AND
717	Context is disease
718	AND
719	Diagnosis is Dementia OR Alzheimer's Disease OR Lewy Body Dementia OR Frontotemporal
720	Dementia OR Non-Aphasic Frontotemporal Dementia
721	
722	in the Voxel-based morphometry database, yielding 394 experiments from 124 articles. These
723	experiments contained 3972 foci, 280 of which were outside the MNI152 mask, leaving 3692 to
724	be loaded into GingerALE. Then the reference map G, with voxels $g_{i,j,k}$, was generated by an
725	ALE meta-analysis using the default parameters: Cluster-level FWE=0.01, Threshold
726	Permutations=1000, P Value=0.001. The reference map is visualized in Supplementary Figure 4.
727	
728	We performed four pairwise comparisons to estimate the amount of overlap between each of the
729	pipelines and G . For each pipeline the comparison was performed by computing an average map
730	\overline{R} , binarizing both it and G, and computing the Dice overlap between the two. The employed
731	approach closely resembles the method of Wang et al. ⁴⁰ , but with multiple thresholds of
732	binarization also for G , and allowed us to plot similarity as a function of the threshold. The full
733	details of the procedure is described in the Supplementary Methods. Additionally, to have a
734	singular numerical basis for comparison, we computed the normalized cross-correlation 46
735	between the (non-binarized) average maps \overline{R} and the reference map G,
736	
737	
	$nCC(\bar{R},G) = \frac{\sum_{i,j,k} (r_{i,j,k} - \bar{r}) (g_{i,j,k} - \bar{g})}{\sqrt{\sum_{i,j,k} (r_{i,j,k} - \bar{r})^2 * \sum_{i,j,k} (g_{i,j,k} - \bar{g})^2}}, r \in \bar{R}, g \in G.$

To facilitate an intuitive understanding of what parts of the brain the dementia-model is focusing

on, we also performed a similar, region-wise comparison. This was done by extracting a subset

of voxels from the average relevance map
$$R_{dementia}$$

742

743
$$\overline{R}_{\rho} = \{r_{i,j,k} \mid (i, j, k) \in \rho\},\$$

744

where ρ is one of 69 regions defined in the Harvard-Oxford cortical and subcortical atlases ⁷⁸. We did the same for *G* and let the mean activation per region for both constitute a tuple

$$\left(\frac{\sum_{r \in R_{\rho}} r}{|R_{\rho}|}, \frac{\sum_{g \in G_{\rho}} g}{|G_{\rho}|}\right)$$

748

plotted Figure 2c. However, since it is non-trivial to determine which aggregation method
corresponds to the most understandable and intuitive interpretation, we also created plots for
tuples of sums,

752

$$\left(\sum_{r\in R_\rho}r\,,\sum_{g\in G_\rho}g\right)$$

753

and maximum values

755

 $\left(\max_{r\in R_{\rho}}r,\max_{g\in G_{\rho}}g\right)$

756

757 per region in Supplementary Figure 10.

To quantify the importance of the spatial locations captured by the various LRP pipelines for

predicting dementia, we implemented a procedure for iteratively occluding parts of the image

based on the relevance maps and observing how the prediction from the dementia model changed

⁷⁶¹ ⁷⁹. Still using the true positives, for each pipeline LRP_{task} for each MRI X_0 we generated a

baseline dementia-prediction \hat{y}_0 and relevance map R_{task} . Then we located the voxel with the

highest amount of relevance in R_{task} and replaced a 15x15x15 cube centred around the voxel

with random uniform noise $\mathcal{U}(0, 1)$, effectively concealing all information contained in this 764 region. Next, we ran the modified image X_{task}^1 through the dementia-model to see how the 765 prediction \hat{y}_{task}^1 changed as a function of the occlusion. Note that injecting a box of random 766 noise into the image is not trivially equivalent to removing information, however we specifically 767 applied the same modification in the random box-augmentation during training and are thus 768 hopeful that the model is invariant to the injection beyond the information removal. We 769 iteratively applied this modify-and-predict procedure, also masking out the regions from the 770 relevant maps between each iteration to minimize overlap of occlusion windows, for 20 771 iterations, producing a list of predictions $[\hat{y}_0, \hat{y}_{task}^1, \hat{y}_{task}^2, \dots, \hat{y}_{task}^{19}]$ plotted for each pipeline in 772 Figure 2d (averaged across all true positives). The rate of decline in these traces indicate the 773 importance of the regions found in the respective relevance maps. We quantified the differences 774 between the pipelines LRP_{task} by calculating the area over the area over their perturbation 775 curves⁷⁹, 776

- 777
- 778

$$AOPC_{task} = \frac{1}{20} \left(\sum_{i=1}^{20} \hat{y}_0 - \hat{y}_{task}^i \right).$$

779

780 Exploratory analyses in the MCI cohort

In the exploratory MCI analyses we used LRP_{dementia} to generate predictions and relevance 781 maps for participants from ADNI who were given an MCI diagnosis at inclusion. We first 782 783 compiled the predictions and relevance maps (and the corresponding timestamps) for each participant at all timepoints into a single data structure we called a morphological record. We 784 then tried to utilize this data structure to differentiate three groups: stable MCI patients (sMCI), 785 progressive MCI patients (pMCI), and those who saw improvement in their cognition throughout 786 787 the data collection phase. The remaining participants, e.g. those who either passed through all three diagnostic stages, or bounced between diagnoses, were excluded. Furthermore, we 788 789 combined the stable and improving cohorts into a non-progressive group (nMCI) to facilitate 790 binary group comparisons in the subsequent analyses.

791

For the first analysis comparing predictions in the two groups, due to variability in the total

number and the frequency of visits between participants, we aimed to create a matched dataset

based on visit history from the nMCI and pMCI cohorts to compare the predictions in the two

groups with reference to a specific timepoint. We first started with all the progressive patients $p_p \in pMCI$ who got a diagnosis at timepoint t_{n+1} , and, for each patient individually, compiled all previous visits t_m , $m \le n$ into a vector h_p representing the time of the visits. The entries d_{t_m} of the vector were the number of days until the diagnosis was given, $t_{n+1} - t_m$. For simplicity we also appended $d_{t_{n+1}} = 0$ to h_p , such that for a single patient

800

802

Then, for each of the non-progressive patients $p_n \in nMCI$ who didn't have a time of diagnosis (e.g. t_{n+1} is not given) we compiled a set H_p of all possible history vectors h_p by varying which visit was chosen as t_0 and a terminal non-diagnosis timepoint t_{n+1} . Next, we defined a costcriterion for matching two histories (with an equal number of visits) as the sum of absolute pairwise differences between the vectors,

- 808
- 809

$$cost(h_1, h_2) = \sum_{m=0}^n |d_{t_m}^{h_1} - d_{t_m}^{h_2}|.$$

 $h_p = [d_{t_0}, d_{t_1}, \dots, d_{t_n}, 0].$

810

For each pair of progressive and non-progressive patients (p_p, p_n) this allowed us to calculate a best possible match, given that the stable patient had a total number of visits equal to or larger than the number of visits for the progressive patient:

814

815
$$match(p_p, p_s) = \begin{cases} \min_{h \in H_{p_s}} cost(h_{p_p}, h) & \exists h \in H_{p_s}(|h| = |h_{p_p}|) \\ \infty & else \end{cases}$$

- 816
- 817

Finally, we compiled the cost of the optimal match from all pairs into a matrix and found the best complete matching by minimizing the total cost across this matrix using the Hungarian algorithm implemented in scipy v1.6.3⁸⁰, such that each patient occurs in at most one pair.

821

822 We estimated differences in predictions \hat{y} between the two groups using a linear mixed model.

823 Specifically, we modelled \hat{y} at all timepoints before the terminal timepoint t_{n+1} as a function of

age, sex (as controlling variables), years to diagnosis, categorical group membership (nMCI,

824

pMCI), and an interaction between years to diagnosis and group. In addition, we had an 825 826 independent intercept and slope per participant. The model was fit the formula API of statsmodels v0.13.2⁸¹ using the formula 827 828 $y \sim age + sex + years$ to diagnosis + C(group) + years to diagnosis: C(group)+ (1 + years to diagnosis | subject)829 on the matched dataset. A full overview of coefficients and p-values can be found in 830 831 Supplementary Table 4. 832 833 Due to the high dimensionality of the relevance maps, we decomposed them with a principal component analysis (PCA) before the final analyses. To fit the PCA we used the non-linearly 834 835 registered relevance maps from a randomly selected timepoint for all MCI patients. Before fitting the model, all relevance maps were smoothed with a constant 3x3x3 blurring kernel using the 836 837 convolution operation from Tensorflow 2.6 to strengthen the signal-to-noise ratio. The PCA was computed using scikit-learn v1.0.2⁸², retaining 64 components (out of 1137 maximally possible) 838 in a component vector $c = [c_0, c_1, ..., c_{63}]$. An axial slice from each of the 64 components 839 visualized in MNI152-space is shown in Supplementary Figure 6. 840 841 842 We fit Cox proportional hazard models using the component vectors as predictors to assess the association between the relevance maps and progression as a function of age. In addition to the 843 components, representing the maps, we controlled for sex in the model. The p-values and 844 coefficients can be found in Supplementary Table 5. To account for covariance between the 845 components and the dementia-prediction \hat{y} we ran an additional model where we divided the 846 patients into ten strata based on \hat{y} . Both models were fit using lifelines v0.27.1 ⁸³. 847 848 To further explore the prognostic efficacy of our pipeline we set up a predictive analysis for 849 predicting progression at multiple, fixed timepoints a given number of months in the future. For 850 each participant p with visits at timepoints t^p , we denoted the last timepoint with an MCI 851

diagnosis t_{neg}^p and the first timepoint with a dementia diagnosis (if present) t_{pos}^p . Using a fixed set of years into the future, $\gamma \in \{1, 2, 3, 4, 5\}$, we constructed a target variable $z_{\gamma}(t^p)$ such that

$$z_{\gamma}(t^{p}) = \begin{cases} 1 & t^{p} + \gamma \ge t_{pos}^{p} \\ 0 & t^{p} + \gamma \le t_{neg}^{p} \\ NA \ else \end{cases}$$

855

856

where the NAs allow for exclusion of all patients where the status at timepoint $t^p + \gamma$ is 857 unknown. For each γ we constructed the target vector z_{γ} across all timepoints for all participants 858 with $z_{\gamma} \neq NA$ and split the constituent patients p into five folds stratified on z_{γ} , sex and age, 859 such that all timepoints from a participant resided in the same fold. Using these folds, we fit 860 logistic regression models to predict z_v with an l_1 -penalty in a nested cross-validation loop, 861 allowing us to both tune the regularization parameter λ and have out-of-sample predictions for 862 all participants. For eligible participants we used all timepoints for training the models, but 863 during testing we sampled a random timepoint per participant to ensure independence between 864 datapoints in the final evaluation. For each γ we fit three models: a baseline model 865 866

$$\mathcal{M}_{base} \coloneqq z_{\gamma} \sim age_{t^p} + sex + age_{t^p} \times sex$$

867

to assess the bias in the dataset with respect to age at the given timepoint t^p and sex, a model using the prediction \hat{y}_{t^p} from the dementia classifier at t^p as a predictor 870

$$\mathcal{M}_{pred} \coloneqq z_{\gamma} \sim age_{t^{p}} + sex + age_{t^{p}} \times sex + \hat{y}_{t^{p}} + age_{t^{p}} \times \hat{y}_{t^{p}}$$

871

and a model including the relevance maps from t^p , represented by the component vector c_{t^p} , 873

874
$$\mathcal{M}_{comp} \coloneqq z_{\gamma} \sim age_{t^p} + sex + age_{t^p} \times sex + \hat{y}_{t^p} + age_{t^p} \times \hat{y}_{t^p} + c_{t^p}$$

875

All models were fit and tuned using the LogisticRegressionCV interface of sklearn v1.0.2 82 . We compared models by measuring the mean AUC across the five folds (Supplementary Table 6).

878 To evaluate clinical applicability we also report accuracy, positive predictive value, sensitivity,

and specificity (Table 2). To determine whether the more complex models represented

significant improvements we employed a one-sided Wilcoxon signed-rank test from scipy v1.9.3

⁸⁰ to do pairwise comparisons between \mathcal{M}_{base} and \mathcal{M}_{pred} , and \mathcal{M}_{pred} , and \mathcal{M}_{comp} across the

882 five out-of-sample AUCs independently.

883

To assess whether the relevance maps were associated with specific cognitive functions we 884 associated aspects of them with performance on various cognitive tests. We first extracted test 885 results from seven neuropsychological batteries which spanned all ADNI waves and contained 886 high-level summary scores from the ADNI website (Supplementary Table 7). We then manually 887 extracted 17 summary scores spanning different, but overlapping, cognitive domains 888 (Supplementary Table 8). The component vectors *c* were used as proxies for the relevance maps, 889 where each c_i represented a template for localization of pathology. We matched 2402 component 890 vectors with test results from 733 MCI patients, forming a basis for the comparison. We then 891 892 calculated the univariate association between cognitive performance according to each of the 17 with each of the dimensions $c_i \in c$, while including age and sex as covariates for correction. To 893 isolate the effect of the localization we also corrected for dementia-prediction, \hat{y} . When a patient 894 895 had multiple potential matches, a random timepoint was selected, and the final number of datapoints used in the analyses varied from 518 to 675. Correction for multiple testing was done 896 with the Benjamini-Hochberg procedure. To ensure the associations were not confounded by 897 collinearities between c and \hat{y} , we also performed an equivalent analysis without correction to 898 observe whether the sign of the coefficients changed. 899

900

901 **References**

- Woo, C.-W., Chang, L. J., Lindquist, M. A. & Wager, T. D. Building better biomarkers: brain
 models in translational neuroimaging. *Nat Neurosci* 20, 365–377 (2017).
- 2. Bethlehem, R. a. I. *et al.* Brain charts for the human lifespan. *Nature* **604**, 525–533 (2022).

- 905 3. Marek, S. *et al.* Reproducible brain-wide association studies require thousands of
- 906 individuals. *Nature* **603**, 654–660 (2022).
- 907 4. Arbabshirani, M. R., Plis, S., Sui, J. & Calhoun, V. D. Single subject prediction of brain
- disorders in neuroimaging: Promises and pitfalls. *NeuroImage* **145**, 137–165 (2017).
- 909 5. Sui, J., Jiang, R., Bustillo, J. & Calhoun, V. Neuroimaging-based Individualized Prediction of
- 910 Cognition and Behavior for Mental Disorders and Health: Methods and Promises. *Biological*
- 911 *Psychiatry* **88**, 818–828 (2020).
- 912 6. Davatzikos, C. Why voxel-based morphometric analysis should be used with great caution
- 913 when characterizing group differences. *NeuroImage* **23**, 17–20 (2004).
- 914 7. Westlin, C. *et al.* Improving the study of brain-behavior relationships by revisiting basic
- assumptions. *Trends in Cognitive Sciences* **27**, 246–257 (2023).
- 8. Bzdok, D. & Ioannidis, J. P. A. Exploration, Inference, and Prediction in Neuroscience and
- Biomedicine. *Trends in Neurosciences* **42**, 251–262 (2019).
- 918 9. LeCun, Y., Bengio, Y. & Hinton, G. Deep learning. *Nature* **521**, 436–444 (2015).
- 919 10. Rudin, C. Stop explaining black box machine learning models for high stakes decisions and
- use interpretable models instead. *Nat Mach Intell* **1**, 206–215 (2019).
- 11. Gauthier S, Webster C, Servaes S, Morais JA, Rosa-Neto P. World Alzheimer Report 2022 –
- 222 Life after diagnosis: Navigating treatment, care and support. (2022).
- 12. Nichols, E. et al. Global, regional, and national burden of Alzheimer's disease and other
- dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
- 925 The Lancet Neurology **18**, 88–106 (2019).

926	13. Vos, T. et a	<i>l.</i> Global burden of 369	diseases and injuries in	204 countries and territories,
-----	------------------	--------------------------------	--------------------------	--------------------------------

- 927 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*
- 928 **396**, 1204–1222 (2020).
- 929 14. World Health Organization. Global status report on the public health response to dementia.
- 930 (2021).
- 15. Nichols, E. *et al.* Estimation of the global prevalence of dementia in 2019 and forecasted
- prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet*
- 933 Public Health 7, e105–e125 (2022).
- 16. Feldman, H. H. *et al.* Diagnosis and treatment of dementia: 2. Diagnosis. *CMAJ* **178**, 825–
- 935 836 (2008).
- 17. Karantzoulis, S. & Galvin, J. E. Distinguishing Alzheimer's disease from other major forms of
 dementia. *Expert Rev Neurother* **11**, 1579–1591 (2011).
- 18. Echávarri, C. *et al.* Co-occurrence of Different Pathologies in Dementia: Implications for
- 939 Dementia Diagnosis. *Journal of Alzheimer's Disease* **30**, 909–917 (2012).
- 940 19. Schneider, J. A. Neuropathology of Dementia Disorders. *CONTINUUM: Lifelong Learning in*
- 941 *Neurology* **28**, 834 (2022).
- 942 20. Ryan, J., Fransquet, P., Wrigglesworth, J. & Lacaze, P. Phenotypic Heterogeneity in
- 943 Dementia: A Challenge for Epidemiology and Biomarker Studies. *Front Public Health* 6, 181
 944 (2018).
- 945 21. Ikram, M. A. *et al.* Brain tissue volumes in relation to cognitive function and risk of
- 946 dementia. *Neurobiology of Aging* **31**, 378–386 (2010).

			-					-				
947	22	McDonald	CR	et al	Relationshin	between	regional	atrophy	v rates and	cognitive (decline	in

- 948 mild cognitive impairment. *Neurobiology of Aging* **33**, 242–253 (2012).
- 949 23. Ferreira, D., Nordberg, A. & Westman, E. Biological subtypes of Alzheimer disease: A
- systematic review and meta-analysis. *Neurology* **94**, 436–448 (2020).
- 951 24. Verdi, S., Marquand, A. F., Schott, J. M. & Cole, J. H. Beyond the average patient: how
- 952 neuroimaging models can address heterogeneity in dementia. *Brain* **144**, 2946–2953
- 953 (2021).
- 25. Rasmussen, J. & Langerman, H. Alzheimer's Disease Why We Need Early Diagnosis.
- 955 *Degener Neurol Neuromuscul Dis* **9**, 123–130 (2019).
- 26. Robinson, L., Tang, E. & Taylor, J.-P. Dementia: timely diagnosis and early intervention. *BMJ*350, h3029 (2015).
- 27. Lu, B. *et al.* A practical Alzheimer's disease classifier via brain imaging-based deep learning
- on 85,721 samples. *Journal of Big Data* **9**, 101 (2022).
- 960 28. Mirzaei, G. & Adeli, H. Machine learning techniques for diagnosis of alzheimer disease, mild
- 961 cognitive disorder, and other types of dementia. *Biomedical Signal Processing and Control*
- 962 **72**, 103293 (2022).
- 963 29. Mirabnahrazam, G. et al. Predicting time-to-conversion for dementia of Alzheimer's type
- using multi-modal deep survival analysis. *Neurobiology of Aging* **121**, 139–156 (2023).
- 30. Castellazzi, G. et al. A Machine Learning Approach for the Differential Diagnosis of
- Alzheimer and Vascular Dementia Fed by MRI Selected Features. Frontiers in
- 967 *Neuroinformatics* **14**, (2020).

968 31. Yao, A. D	., Cheng, D. L	., Pan, I. & Kitamura,	, F. Deep	Learning in	Neuroradiolo	gy: A
-------------------	----------------	------------------------	-----------	-------------	--------------	-------

- 969 Systematic Review of Current Algorithms and Approaches for the New Wave of Imaging
- 970 Technology. *Radiology: Artificial Intelligence* **2**, e190026 (2020).
- 971 32. Kundu, S. Al in medicine must be explainable. *Nat Med* **27**, 1328–1328 (2021).
- 33. Samek, W., Montavon, G., Vedaldi, A., Hansen, L. K. & Müller, K.-R. Explainable AI:
- 973 Interpreting, Explaining and Visualizing Deep Learning. (Springer Nature, 2019).
- 974 34. Barredo Arrieta, A. et al. Explainable Artificial Intelligence (XAI): Concepts, taxonomies,
- opportunities and challenges toward responsible Al. *Information Fusion* **58**, 82–115 (2020).
- 976 35. Samek, W. & Müller, K.-R. Towards Explainable Artificial Intelligence. in *Explainable AI*:
- 977 Interpreting, Explaining and Visualizing Deep Learning (eds. Samek, W., Montavon, G.,
- Vedaldi, A., Hansen, L. K. & Müller, K.-R.) 5–22 (Springer International Publishing, Cham,
- 979 2019). doi:10.1007/978-3-030-28954-6_1.
- 980 36. Simonyan, K., Vedaldi, A. & Zisserman, A. Deep Inside Convolutional Networks: Visualising
- 981 Image Classification Models and Saliency Maps. Preprint at
- 982 https://doi.org/10.48550/arXiv.1312.6034 (2014).
- 37. Bach, S. *et al.* On Pixel-Wise Explanations for Non-Linear Classifier Decisions by Layer-Wise
 Relevance Propagation. *PLOS ONE* 10, e0130140 (2015).
- 38. Martin, S. A., Townend, F. J., Barkhof, F. & Cole, J. H. Interpretable machine learning for
 dementia: A systematic review. *Alzheimer's & Dementia* (2023).
- 987 39. Böhle, M., Eitel, F., Weygandt, M. & Ritter, K. Layer-Wise Relevance Propagation for
- 988 Explaining Deep Neural Network Decisions in MRI-Based Alzheimer's Disease Classification.
- 989 Frontiers in Aging Neuroscience **11**, (2019).

990 40. Wang, D. et al. Deep neural network heatmaps capture Alzheimer's disease	patterns
--	----------

- reported in a large meta-analysis of neuroimaging studies. *NeuroImage* **269**, 119929 (2023).
- 992 41. Dyrba, M. et al. Improving 3D convolutional neural network comprehensibility via
- 993 interactive visualization of relevance maps: evaluation in Alzheimer's disease. Alzheimer's
- 994 *Research & Therapy* **13**, 191 (2021).
- 42. Dyrba, M., Pallath, A. H. & Marzban, E. N. Comparison of CNN Visualization Methods to Aid
- 996 Model Interpretability for Detecting Alzheimer's Disease. in *Bildverarbeitung für die Medizin*
- 997 2020 (eds. Tolxdorff, T. et al.) 307–312 (Springer Fachmedien, Wiesbaden, 2020).
- 998 doi:10.1007/978-3-658-29267-6_68.
- 999 43. Martin, S. A., Townend, F. J., Barkhof, F. & Cole, J. H. Interpretable machine learning for
- dementia: A systematic review. *Alzheimer's & Dementia* **19**, 2135–2149 (2023).
- 1001 44. Kohlbrenner, M. *et al.* Towards Best Practice in Explaining Neural Network Decisions with
- 1002 LRP. in 2020 International Joint Conference on Neural Networks (IJCNN) 1–7 (2020).
- 1003 doi:10.1109/IJCNN48605.2020.9206975.
- 1004 45. Eickhoff, S. B., Bzdok, D., Laird, A. R., Kurth, F. & Fox, P. T. Activation Likelihood Estimation
 1005 meta-analysis revisited. *Neuroimage* 59, 2349–2361 (2012).
- 1006 46. Briechle, K. & Hanebeck, U. D. Template matching using fast normalized cross correlation. in
- 1007 (eds. Casasent, D. P. & Chao, T.-H.) 95–102 (Orlando, FL, 2001). doi:10.1117/12.421129.
- 1008 47. Eitel, F. & Ritter, K. Testing the Robustness of Attribution Methods for Convolutional Neural
- 1009 Networks in MRI-Based Alzheimer's Disease Classification. in Interpretability of Machine
- 1010 Intelligence in Medical Image Computing and Multimodal Learning for Clinical Decision

- 1011 Support (eds. Suzuki, K. et al.) 3–11 (Springer International Publishing, Cham, 2019).
- 1012 doi:10.1007/978-3-030-33850-3_1.
- 1013 48. Erasmus, A., Brunet, T. D. P. & Fisher, E. What is Interpretability? *Philos. Technol.* **34**, 833–
- 1014
 862 (2021).
- 1015 49. Ghassemi, M., Oakden-Rayner, L. & Beam, A. L. The false hope of current approaches to
- 1016 explainable artificial intelligence in health care. *The Lancet Digital Health* **3**, e745–e750
- 1017 (2021).
- 1018 50. Amann, J. *et al.* To explain or not to explain?—Artificial intelligence explainability in clinical
- 1019 decision support systems. *PLOS Digital Health* **1**, e0000016 (2022).
- 1020 51. Adebayo, J. et al. Sanity Checks for Saliency Maps. arXiv:1810.03292 [cs, stat] (2020).
- 1021 52. Kindermans, P.-J. *et al.* The (Un)reliability of Saliency Methods. in *Explainable Al:*
- 1022 Interpreting, Explaining and Visualizing Deep Learning (eds. Samek, W., Montavon, G.,
- 1023 Vedaldi, A., Hansen, L. K. & Müller, K.-R.) 267–280 (Springer International Publishing, Cham,
- 1024 2019). doi:10.1007/978-3-030-28954-6_14.
- 1025 53. Nie, X. *et al.* Subregional Structural Alterations in Hippocampus and Nucleus Accumbens
- 1026 Correlate with the Clinical Impairment in Patients with Alzheimer's Disease Clinical
- Spectrum: Parallel Combining Volume and Vertex-Based Approach. *Frontiers in Neurology* 8,
 (2017).
- 1029 54. Poulin, S. P., Dautoff, R., Morris, J. C., Barrett, L. F. & Dickerson, B. C. Amygdala atrophy is
- prominent in early Alzheimer's disease and relates to symptom severity. *Psychiatry Res* **194**,
- 1031 **7–13 (2011)**.

- 1032 55. Van Hoesen, G. W., Augustinack, J. C., Dierking, J., Redman, S. J. & Thangavel, R. The
- 1033 parahippocampal gyrus in Alzheimer's disease. Clinical and preclinical neuroanatomical
- 1034 correlates. *Ann N Y Acad Sci* **911**, 254–274 (2000).
- 1035 56. Visser, P. J. *et al.* Medial temporal lobe atrophy and memory dysfunction as predictors for
- dementia in subjects with mild cognitive impairment. *J Neurol* **246**, 477–485 (1999).
- 1037 57. Echávarri, C. *et al.* Atrophy in the parahippocampal gyrus as an early biomarker of
- 1038 Alzheimer's disease. *Brain Struct Funct* **215**, 265–271 (2011).
- 1039 58. Dickerson, B. C. et al. Alzheimer-signature MRI biomarker predicts AD dementia in
- 1040 cognitively normal adults. *Neurology* **76**, 1395–1402 (2011).
- 1041 59. Rafii, M. S. & Aisen, P. S. Detection and treatment of Alzheimer's disease in its preclinical
- 1042 stage. *Nat Aging* **3**, 520–531 (2023).
- 1043 60. Frisoni, G. B. *et al.* Dementia prevention in memory clinics: recommendations from the
- 1044 European task force for brain health services. *The Lancet Regional Health Europe* **26**,
- 1045 (2023).
- 1046 61. de Vugt, M. E. & Verhey, F. R. J. The impact of early dementia diagnosis and intervention on 1047 informal caregivers. *Progress in Neurobiology* **110**, 54–62 (2013).
- 1048 62. Leonardsen, E. H. *et al.* Deep neural networks learn general and clinically relevant
- 1049 representations of the ageing brain. *NeuroImage* **256**, 119210 (2022).
- 1050 63. Mårtensson, G. *et al.* The reliability of a deep learning model in clinical out-of-distribution
- 1051 MRI data: A multicohort study. *Medical Image Analysis* 66, 101714 (2020).
- 1052 64. Herzog, C. On the Ethical and Epistemological Utility of Explicable AI in Medicine. *Philos*.
- 1053 *Technol.* **35**, 50 (2022).

- 1054 65. Petersen, R. C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical
- 1055 characterization. *Neurology* **74**, 201–209 (2010).
- 1056 66. Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W. & Smith, S. M. FSL.
- 1057 *NeuroImage* **62**, 782–790 (2012).
- 1058 67. Ségonne, F. *et al.* A hybrid approach to the skull stripping problem in MRI. *Neuroimage* **22**,
- 1059 1060–1075 (2004).
- 1060 68. Jenkinson, M. & Smith, S. A global optimisation method for robust affine registration of
- 1061 brain images. *Med Image Anal* 5, 143–156 (2001).
- 1062 69. Gong, W., Beckmann, C. F., Vedaldi, A., Smith, S. M. & Peng, H. Optimising a Simple Fully
- 1063 Convolutional Network for Accurate Brain Age Prediction in the PAC 2019 Challenge.
- 1064 Frontiers in Psychiatry **12**, (2021).
- 1065 70. Peng, H., Gong, W., Beckmann, C. F., Vedaldi, A. & Smith, S. M. Accurate brain age
- 1066 prediction with lightweight deep neural networks. *Medical Image Analysis* **68**, 101871
- 1067 (2021).
- 71. Abadi, M. *et al.* TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed
 Systems. 19 (2015).
- 1070 72. Chollet, F. & others. Keras. https://github.com/fchollet/keras (2015).
- 1071 73. Smith, L. N. Cyclical Learning Rates for Training Neural Networks. *arXiv:1506.01186 [cs]*1072 (2017).
- 1073 74. Guillemot, M., Heusele, C., Korichi, R., Schnebert, S. & Chen, L. Breaking Batch
- 1074 Normalization for better explainability of Deep Neural Networks through Layer-wise
- 1075 Relevance Propagation. *arXiv:2002.11018 [cs, stat]* (2020).

23291592; this version posted February 22, 2024. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2023.06.22 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 75. Montavon, G., Binder, A., Lapuschkin, S., Samek, W. & Müller, K.-R. Layer-Wise Relevance 1076
- 1077 Propagation: An Overview. in Explainable AI: Interpreting, Explaining and Visualizing Deep
- Learning (eds. Samek, W., Montavon, G., Vedaldi, A., Hansen, L. K. & Müller, K.-R.) 193–209 1078
- (Springer International Publishing, Cham, 2019). doi:10.1007/978-3-030-28954-6 10. 1079
- 1080 76. Brett, M. et al. nipy/nibabel: 3.2.2. Zenodo https://doi.org/10.5281/zenodo.6617121
- (2022). 1081

- 1082 77. Laird, A. R., Lancaster, J. L. & Fox, P. T. BrainMap: the social evolution of a human brain mapping database. *Neuroinformatics* **3**, 65–78 (2005).
- 78. Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral 1084
- 1085 cortex on MRI scans into gyral based regions of interest. *Neuroimage* **31**, 968–980 (2006).
- 79. Samek, W., Binder, A., Montavon, G., Lapuschkin, S. & Müller, K.-R. Evaluating the 1086
- 1087 Visualization of What a Deep Neural Network Has Learned. IEEE Transactions on Neural
- 1088 Networks and Learning Systems 28, 2660–2673 (2017).
- 80. Virtanen, P. et al. SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python. 1089
- *Nature Methods* **17**, 261–272 (2020). 1090
- 1091 81. Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with Python. in
- 92–96 (Austin, Texas, 2010). doi:10.25080/Majora-92bf1922-011. 1092
- 1093 82. Pedregosa, F. et al. Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research 12, 2825–2830 (2011). 1094
- 83. Davidson-Pilon, C. lifelines: survival analysis in Python. Journal of Open Source Software 4, 1095
- 1317 (2019). 1096
- 1097

1098 Author contributions:

- 1099 Conceptualization: EHL, TW, LTW, YW. Data curation: KP, EW, GS. Formal analysis: EHL.
- 1100 Funding acquisition: OAA, YW. Investigation: EHL, JMR, DVP, TK, AM, OAA, TW, LTW,
- 1101 YW. Methodology: EHL, EG, ND, TS, ØS, TW, LTW, YW. Project administration: GS, OAA,
- 1102 LTW, YW. Software: EHL. Supervision: TW, LTW, YW. Validation: EHL. Visualization: EHL.
- 1103 Writing original draft: EHL, TW, LTW, YW. Writing review & editing: KP, EG, ND, TS,
- 1104 JMR, DVP, ØS, TK, EW, AM, GS, OAA.

1105 Acknowledgements

1106 This work was funded by the UiO:LifeScience Convergence Environment (project: 4MENT), the

- 1107 Research Council of Norway (302854), and the European Research Council under the European
- 1108 Union's Horizon 2020 research and Innovation program (802998). The Southern and Eastern
- 1109 Norway Regional Health Authority supported the study through funding for KP but was not
- 1110 involved in conducting the study or in preparation of the manuscript. TW acknowledges funding
- 1111 from the German Research Foundation (DFG) Emmy Noether: 513851350. The work was
- 1112 performed on the Service for Sensitive Data (TSD) platform, owned by the University of Oslo,
- operated, and developed by the TSD service group at the University of Oslo IT-Department
- 1114 (USIT). We also acknowledge the computational resources provided by UNINETT Sigma2 the
- 1115 National Infrastructure for High Performance Computing and Data Storage in Norway with
- 1116 project no. (nn9769k/ns9769k).

1117 Competing interests:

1118 KP report work with Roche BN29553 and Novo Nordisk NN6535-4730 trials; All other authors

1119 declare that they have no competing interests.

1120 Data availability

- 1121 The data used in this study were gathered from various sources, an overview including
- acknowledgements of their respective funding sources is provided in Supplementary Table 1.
- 1123 Among others, data used in the preparation of this article was obtained from the Alzheimer's
- 1124 Disease Neuroimaging Initiative (ADNI, see adni.loni.usc.edu for further details), the Australian
- 1125 Imaging Biomarkers and Lifestyle flagship study of ageing (AIBL, <u>www.aibl.csiro.au</u>) the

- 1126 AddNeuroMed consortium, and MIRIAD (www.nitrc.org/projects/miriad). The investigators
- 1127 within these studies contributed to the design and implementation of the data collection process
- but did not participate in the analysis or writing of this report, and this publication is solely the
- 1129 responsibility of the authors.

1130 Code availability:

- 1131 The trained model and explainable pipeline and the underlying code will be made available at
- 1132 <u>https://github.com/estenhl/pyment-public</u> upon publication. Generic code for generating
- 1133 explanations for 3D CNNs is available at <u>https://github.com/estenhl/keras-explainability</u>.